Literature DB >> 10983636

Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes.

E Grene1, D A Newton, E A Brown, J A Berzofsky, S Gattoni-Celli, G M Shearer.   

Abstract

OBJECTIVE: The present study was designed to determine whether the HLA allogeneic T helper response stimulated by semi-allogeneic cell lines could be used as an in vitro model of immune-based therapy to stimulate HIV-specific cytotoxic T lymphocytes. DESIGN AND METHODS: Semi-allogeneic cell hybrids were obtained by the fusion of peripheral blood mononuclear cells from HIV-infected patients with the allogeneic beta2-microglobulin-deficient FO1-12 melanoma cell line. These hybrids were used as antigen presenting cells for HIV envelope peptide (env)-specific cytotoxic assays.
RESULTS: The hybrid cell lines express HLA class I and II antigens from both parental cells, as well as the CD86 costimulatory molecule. HIV-specific cytotoxic T lymphocyte activity was obtained when patients' peripheral blood mononuclear cells were costimulated with env peptides plus semi-allogeneic hybrids, in contrast with stimulation with either env or hybrid cells alone. Thus, the semi-allogeneic hybrids enhanced HIV-specific killing of target cells.
CONCLUSIONS: Irradiated, semi-allogeneic cell hybrids engineered for individual AIDS patients provide efficient and simultaneous co-recognition of HLA allogeneic determinants and viral antigenic determinants presented by self-HLA molecules on the same antigen presenting cells and results in the generation of enhanced HIV-specific cytotoxic T lymphocyte activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10983636     DOI: 10.1097/00002030-200007280-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  A therapeutic cancer vaccine against GL261 murine glioma.

Authors:  Mark S Kindy; Jin Yu; Hong Zhu; Michael T Smith; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2016-01-05       Impact factor: 5.531

2.  Semi-allogeneic vaccines and tumor-induced immune tolerance.

Authors:  Jin Yu; Mark S Kindy; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2009-01-08       Impact factor: 5.531

3.  Semi-allogeneic vaccine for T-cell lymphoma.

Authors:  Jin Yu; Mark S Kindy; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2007-08-08       Impact factor: 5.531

4.  Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals.

Authors:  Paula M Acierno; Danforth A Newton; Edwin A Brown; Lou Anne Maes; John E Baatz; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2003-08-14       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.